COMPARATIVE PHARMACOECONOMIC ANALYSIS OF RIVAROXABAN AND WARFARIN USAGE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Objective: complex pharmacoeconomic evaluation of warfarin replacement with rivaroxaban one of the direct oral anticoagulant (DOAC) for the treatment of patients with non-valvular atrial fibrillation and high risk of thromboembolia with poor international normalized ratio control.

Materials and methods: A pharmacoeconomic model was designed to evaluate clinical outcomes of rivaroxaban therapy in compare with warfarin (with poor international normalized ratio control), economic impact was also calculated using budget impact analysis. Direct medical costs included drug costs, inpatient costs and costs of patient rehabilitation with cardiovascular complications. Moreover, indirect costs were simulated, including Gross Domestic Product loss due to disability or mortality of patients. Results were calculated on total number of patients from Russian Federation with non-valvular atrial fibrillation and high risk of thromboembolism, receiving rivaroxaban and warfarin (total of 278,175 patients). Patients with non-valvular atrial fibrillation on other anticoagulant therapies (130,305 patients) were not included in the analysis. Modeling horizon was 12 months.

Results: in the analyzed population replacement of warfarin with poor international normalized ratio control with rivaroxaban makes it possible to additionally prevent 3,778 stroke events (-33% in compare with warfarin), 170 events of systemic thromboembolisms (-31%), 1,977 events of fatal bleeding (-11%) and 247 events of myocardial infarctions (-6%). Generally, patients transfer to rivaroxaban therapy reduces mortality by 30% (2,908 cases). Budget impact analysis demonstrated, that despite of the increased drug therapy costs by 2,306.1 million RUR, replacement of warfarin in the part of patients with rivaroxaban reduces costs, related to the complications treatment by 543.0 million RUR, rehabilitation costs - by 461.6 million RUR, INR control costs - by 480.3 million RUR, decline in GDP due to disability and mortality - by 2,988.5 million RUR. Thereby, replacement of patients with poor international normalized ratio control from warfarin to rivaroxaban reduces costs, related to the complications treatment of atrial fibrillation and GDP loss by 2,174.0 million rub.

Conclusion: Warfarin replacement with rivaroxaban in patients with non-valvular atrial fi brillation and high risk of thromboembolism with poor international normalized ratio control is the most efficient from clinical and economic points.

1. Здравоохранение в России. 2017: Статистический сборник. Росстат. - М., 2017. - 170 с. [Health care in Russia. 2017: Statistical Digest. Rosstat. M., 2017, 170 p. (In Russ.)] ISBN 978-5-89476-450-4.

2. Заболеваемость всего населения России в 2017 году. Статистические материалы. Часть II. Министерство здравоохранения Российской Федерации [Электронный ресурс]. URL: https://www.rosminzdrav. ru/ministry/61/22/stranitsa-979/statisticheskie-iinformatsionnye-materialy/statisticheskiy-sbornik-2017- god (дата обращения 28.08.2019) [The Morbidity of the Population of Russia in 2017. Statistical materials. Part II Ministry of Health of the Russian Federation [Electronic resource]. URL: https://www.rosminzdrav. ru/ministry/61/22/stranitsa-979/statisticheskie-iinformatsionnye-materialy/statisticheskiy-sbornik-2017- god (date of the application 28.08.2019) (In Russ.)].

3. Pisters R, van Oostenbrugge RJ, Knottnerus IL, et al. The likelihood of decreasing strokes in atrial fi brillation patients by strict application of guidelines. 2010 Jun;12(6):779-84. DOI: 10.1093/europace/euq080.

4. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837- 47. doi: 10.1161/CIRCULATIONAHA.113.005119.

5. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893-2962. DOI: 10.1093/eurheartj/ehw210

6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983-8. DOI: 10.1161/01. str.22.8.983.

7. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996 Oct;27(10):1760-4. DOI: 10.1161/01.str.27.10.1760.

8. Ревишвили А.Ш., Шляхто Е.В., Сулимов В.А. и др. Диагностика и лечение фибрилляции предсердий (Рекомендации РКО, ВНОА, АССХ). В кн: Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М: - ВНОА - 2017 - с. 464-701. [Revishvili A.Sh., Shlyahto E.V., Sulimov V.A. et al. Diagnosis and management of atrial fi brillation. Clinical recommendations. M.: 2017. 464 p. (In Russ.)] ISBN 978-5-9500922-0-6.

9. Гусев Е. И., Коновалов А. Н., Скворцова В. И. и др. Неврология. Национальное руководство. 2009, 1064 с. [Gusev E.I., Konovalov A.N., Skvortsova V.l. et al. Neurology. National leadership. 2009, 1064 p. (In Russ.)]

10. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968-77. DOI: 10.1160/TH11-05- 0353.

11. Линчак Р.М, Компаниец О.Г., Недбайкин А.М. и др. Каковы реалии назначения и контроля антитромботической терапии при фибрилляции предсердий в амбулаторной практике. Кардиология. 2015;55(6):34- 39. [Linchak R.M., Kompaniets O.G., Nedbaykin A.M., et al. What are the realities of prescribing and controlling antithrombotic therapy in atrial fibrillation in outpatient practice. Cardiologiia. 2015;55(6):34-9. (In Russ.)]. DOI:10.18565/cardio.201 5.6.34-39.

12. Шубик Ю.В. Особенности профилактики тромбоэмболических осложнений у больных с фибрилляцией предсердий в России. Вестник аритмологии, 2017; (87): 5-6. [Shubik Y.V. Peculiar Features of Prevention of Thromboembolic Events in Atrial Fibrillation in Russia. Journal of Arrhythmology. 2017;(87):5-6. (In Russ.)].

13. Рычков А.Ю., Хорькова Н.Ю., Минулина А.В. Как изменилось применение антикоагулянтов у пациентов с неклапанной фибрилляцией предсердий. Вестник аритмологии, 2017; (87): 29-32. [Rychkov A.Y., Khorkova N.Y., Minulina A.V. Trends in Use of Anticoagulants in Patients with Non-Valvular Atrial Fibrillation. Journal of Arrhythmology. 2017;(87):29-32. (In Russ.)].

14. Steff el J, Verhamme P, Potpara T.S, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330-1393. DOI: 10.1093/eurheartj/ehy136.

15. Шубик Ю.В. Антитромботическая терапия при фибрилляции предсердий. Вестник аритмологии, 2014;(75): 50-75. [Shubik Y.V. Antithrombotic therapy in atrial fibrillation / Journal of Arrhythmology. 2014;(75): 50-75. (In Russ.)].

16. Patel MR, Mahaff ey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. DOI: 10.1056/ NEJMoa1009638

17. Connolly S., Ezekowitz M., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. DOI: 10.1056/ NEJMoa0905561

18. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fi brillation. N Engl J Med. 2011 Sep 15;365(11):981-92. DOI: 10.1056/NEJMoa1107039

19. ФМ. Фармация и Медицина, 2019 (7) [Электронный ресурс]. URL: https://dsm.ru/news/602/ (дата обращения 06.10.2019). [PhM. Pharmacy and Medicine, 2019 (7) [Electronic resource]. URL: https://dsm.ru/news/602/ (date of the application 06.10.2019) (In Russ.)]

20. Панченко Е.П., Аксета Г., Либис Р.А. и др. Характеристика факторов риска и назначаемой антитромботической терапии у пациентов с впервые диагностированной неклапанной фибрилляцией предсердий в Российской Федерации (по результатам международного регистра GARFIELD-AF). Кардиология, 2017;57(4):38-45]. [Panchenko EP, Akseta G., Libis R.A. et al. Characteristics of risk factors and prescribed antithrombotic therapy in patients with newly diagnosed non-valvular atrial fibrillation in the Russian Federation (according to the results of the international register GARFIELD-AF). Cardiologiia. 2017;57(4):38-45. (In Russ.)] DOI:10.18565/cardio. 2017.4.38-44.

21. Haas S, Ten Cate H, Accetta G, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One. 2016 Oct 28;11(10): DOI:10.1371/journal.pone.0164076

22. Постановление Правительства РФ от 10.12.2018 N 1506 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2019 год и на плановый период 2020 и 2021 годов». [Электронный ресурс]. URL: https://www. rulaws.ru/goverment/Postanovlenie-Pravitelstva-RFot-10.12.2018-N-1506/ (дата обращения 06.10.2019) [Decree of the Government of the Russian Federation of December dated December 12, 2018 N 1506 “About the Program of State Guarantees for the Free Provision of Medical Assistance to Citizens for 2019 and for the Planning Period 2020 and 2021” [Electronic resource]. URL: https://www.rulaws.ru/goverment/PostanovleniePravitelstva-RF-ot-10.12.2018-N-1506/ (date of the application 06.10.2019)]

23. Письмо ФФОМС от 03.12.2018 г. N 15031/26-1/и «Инструкция по группировке случаев, в том числе правила учета классификационных критериев, и подходам к оплате медицинской помощи в амбулаторных условиях по подушевому нормативу финансирования». [Электронный ресурс]. URL: https://www.rulaws.ru/acts/Pismo-FFOMS-ot-03.12.2018-N-15031_26-1_i/ (дата обращения 06.10.2019). [Letter of the FFOMS dated December 03, 2018 N 15031/26-1/i “Instructions on the grouping of cases, including the rules for considering classification criteria, and approaches to paying for medical care on an outpatient basis according to the per capita funding standard” [Electronic resource]. URL: https://www.rulaws.ru/acts/Pismo-FFOMS-ot-03.12.2018- N-15031_26-1_i/ (date of the application 06.10.2019)]

24. The Atlas of Heart Disease and Stroke. [Электронный ресурс]. URL: https://www.who.int/cardiovascular_ diseases/resources/atlas/en/ (дата обращения 06.10.2019).

25. Федеральная служба государственной статистики. [Электронный ресурс] URL: http://www.gks.ru (дата обращения 18.08.2019) [Federal State Statistics Service [Electronic resource]. URL: http://www.gks.ru (date of the application 18.08.2019)].

26. Ягудина Р.И., Серпик В.Г., Угрехелидзе Д.Т. Методологические основы анализа «влияния на бюджет». Фармакоэкономика: теория и практика, 2015; 3 (4): 5-8. [Yagudina R.I., Serpik V.G., Ugrekhelidze D.T. Methodological basis for budget impact analysis // Pharmacoeconomics: theory and practice. 2015; 3 (4): 9-12 (In Russ.)] DOI: 10.30809/phe.4.2015.5

27. Куликов А.Ю., Проценко М.В., Сердечная Е.В. Фармакоэкономический анализ включения ривароксабана в текущие алгоритмы профилактики инсультов у пациентов с фибрилляцией предсердий. Кардиология, 2016; 56 (11): 71-77. [Kulikov A.Y., Protsenko M.V., Serdechnaya E.V. Pharmacoeconomic Analysis of the Inclusion of Rivaroxaban in the Current Algorithms Prevention of the Stroke in Patients with Atrial Fibrillation // Kardiologiia. 2016; 56 (11): 71-77 (In Russ.)] DOI: 10.18565/cardio.2016.11.71-77.